Trial Outcomes & Findings for Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use (NCT NCT05521880)

NCT ID: NCT05521880

Last Updated: 2026-07-24

Results Overview

One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. So cure or completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks could not be assessed, and no statistical analyses were performed.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

1 participants

Primary outcome timeframe

12 weeks

Results posted on

2026-07-24

Participant Flow

One patient screen failed and one patient opted out of the study after initial visit

One patient screen failed and one patient opted out of the study after initial visit

Participant milestones

Participant milestones
Measure
Study Arm
One patient screen failed and one patient opted out of the study after initial visit
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
Overall Study
STARTED
1
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
1
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Study Arm
n=1 Participants
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
Total
n=1 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Age, Categorical
Between 18 and 65 years
1 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
1 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Age, Categorical
>=65 years
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Sex: Female, Male
Female
1 Participants
n=9 Participants
0 Participants
n=27 Participants
1 Participants
n=267 Participants
Sex: Female, Male
Male
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
Asian
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
Black or African American
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
White
1 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
1 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=27 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
0 Participants
n=267 Participants • One participant was enrolled but withdrew after the initial visit before baseline assessments were completed. Therefore, no evaluable baseline characteristic data were available.
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants
n=9 Participants
0 Participants
n=27 Participants
1 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants

PRIMARY outcome

Timeframe: 12 weeks

Population: Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported

One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. So cure or completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks could not be assessed, and no statistical analyses were performed.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Frequency of Clinically Assessed Cure, Completion (no Need for Further Parenteral Antimicrobial Therapy) or Transition to Suppressive Antimicrobial Therapy at 12 Weeks
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. Consequently, no participants contributed evaluable data for this outcome measure, and no statistical analyses were performed.

One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. Consequently, no participants contributed evaluable data(Frequency of non-adherence to antimicrobial therapy) for this outcome measure, and no statistical analyses were performed.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Frequency of Non-adherence to Antimicrobial Therapy (Lack of Follow up or Any Subsequent Scheduled Parenteral Antimicrobial Dose Administration)
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Frequency of Hospital Readmission at 30 Days Post Discharge and at 90 Days Post Discharge
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Proportion of Patients With Drug Related AE
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rate of Follow up at Scheduled in Person Medication for Opioid Use Disorder (MOUD) Visit and Frequency of Follow up/no Shows at Follow up Dosing Visits for MOUD at 12 Weeks
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Proportion of Patients With Positive Urine Drug Screen
0 participants
0 participants

SECONDARY outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Evaluate Effect of Medication for Opioid Use Disorder (MOUD) Follow up on Cure/Completion or Transition to Suppressive Antimicrobial Therapy.
0 participants
0 participants

SECONDARY outcome

Timeframe: 6 months

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rate of Direct Acting Antiviral (DAA) Initiation for Hepatitis C (HCV) in Patients Enrolled and Rate of DAA Completion and SVR for HCV in Patients Enrolled
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rates of New HIV Infection
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rates of Occurrence of New Bacterial Infection Related to OUD
0 participants
0 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 weeks

Population: One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Outcome measures

Outcome measures
Measure
Historical Outcomes With Standard of Care Treatment
Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared. Because no participant completed study visits to timeline where outcomes could be assessed this cannot be reported
Study Arm
One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rates of High Risk Behavior at Baseline and During and Post Completion of Antimicrobial Therapy and Follow up.
0 participants
0 participants

Adverse Events

Adverse Outcomes for Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Study Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder

University of Maryland Baltimore

Phone: 4107064750

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place